Brown, Lisle/Cummings, Inc. Sangamo Therapeutics, Inc Transaction History
Brown, Lisle/Cummings, Inc.
- $335 Billion
- Q4 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 1,525 shares of SGMO stock, worth $1,784. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,525
Previous 1,525
-0.0%
Holding current value
$1,784
Previous $1.32 Million
17.79%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SGMO
# of Institutions
134Shares Held
52.5MCall Options Held
1.02MPut Options Held
1.61M-
Vanguard Group Inc Valley Forge, PA9.37MShares$11 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT9.23MShares$10.8 Million0.05% of portfolio
-
State Street Corp Boston, MA5.02MShares$5.87 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$5.5 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.08MShares$3.61 Million0.0% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $183M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...